<DOC>
	<DOCNO>NCT00596206</DOCNO>
	<brief_summary>To assess efficacy response rate 3-months two dose regimen leflunomide DMARDs-naive patient present early-RA use American College Rheumatology 20 % response rate . To assess clinical efficacy 1-month 3-month use complementary efficacy criterion ( ACR 50 , ACR 70 , DAS 28 ) group treatment , To assess clinical biological safety use standard blood monitoring , TEAED SAE group treatment , To evaluate treatment modification ; particularity leflunomide concomitant use AINS corticoid .</brief_summary>
	<brief_title>Leflunomide EfficAcy Response Related Dosing Regimen Early Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis active rheumatoid arthritis previous 6 month ( accord ACR guideline ) Must active disease initiate DMARDs ( Disease Modifying AntiRheumatic Drugs ) Patient present history inflammatory joint disease Patient ongoing previous StevensJohnson syndrome , toxic epidermal necrolysis erythema multiforme Patient significantly impair bone marrow function significant anaemia , leucopenia thrombocytopenia due cause active rheumatoid arthritis Persistent infection severe infection within 3 month enrollment , Uncontrolled hypertension , uncontrolled diabetes , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , terminal illness medical condition , opinion investigator , would put patient risk participate study , Clinically relevant cardiovascular , hepatic , neurological , endocrine , major systemic disease make implementation protocol interpretation study result difficult Severe hypoproteinemia ( e.g. , case severe liver disease nephrotic syndrome ) serum albumin &lt; 3.0 g/dl Moderate severe impairment renal function , know serum creatinine &gt; 133 mcmol/L ( 1.5 mg/dl ) Patient history recent clinically significant drug alcohol abuse Impairment liver function persist ALT ( SGPT ) elevations 2fold upper limit normal Pregnancy Breastfeeding Women childbearing potential , except fulfill specific condition , Men wish father child course study within 24 month thereafter ( 3 month washout procedure ) Patient congenital acquire severe immunodeficiency , history cancer lymphoproliferative disease , patient receive total lymphoid irradiation Known HIV positive status Known positive serology hepatitis B C Patient hypersensitivity excipients tablet leflunomide Previous therapy time : DMARD include methotrexate , oral injectable gold salt , chloroquine , hydroxychloroquine , ciclosporin , azathioprine , methotrexate , sulfasalazine D penicillamine alkylating agent , e.g. , cyclophosphamide , chlorambucil , biological agent , e.g. , interferon , monoclonal antibody , growth factor , cytokine investigational drug antimetabolites opiate Therapy within previous 4 week : oral corticosteroid exceed prednisolone equivalent 10 mg/day parenteral intraarticular corticoid injection The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>